Skip to main content
. 2016 May 3;52(2):849–862. doi: 10.1111/1475-6773.12501

Table 2.

Correlation in Quality Measures Across HRRs, 2007–2009

Mammography DMARD Treatment for Rheum. Arthritis Bronco COPD Depress Tx Pneu Antibx Hemo A1C Test Lower Back Imaging 30‐Day Readmission Chronic PQI Acute PQI
Mammography 1.00
DMARD Treatment for Rheum. Arthritis 0.29a 1.00
Bronco COPD 0.30a 0.49a 1.00
Depress Tx 0.42a 0.26a 0.30a 1.00
Pneu Antibx 0.38a 0.61a 0.71a 0.53a 1.00
Hemo A1C Test −0.01 0.20 0.14 −0.03 0.21a 1.00
Lower back imaging 0.25a 0.07 0.23 0.52a 0.32a 0.11 1.00
30‐day readmission −0.09 −0.03 0.07 0.22 0.04 0.04 <0.01 1.00
Chronic PQI 0.29a 0.15 0.22 0.55a 0.41a −0.05 0.62a 0.03 1.00
Acute PQI 0.24a 0.29a 0.22 0.45a 0.48a −0.19a 0.67a 0.24a 0.85a 1.00

Table displays pairwise correlations of 10 quality measures across the 306 HRRs. PQI composites and 30‐day readmissions are adjusted for age, sex, age/sex interaction, and health status. Each measure was coded such that a higher score was associated with better performance for each of the indicators (high scores for readmissions and PQIs represent good quality.) Bonferroni correction adjusted for multiple comparisons for the 45 pairwise comparisons (individual tests at α = .001).

DMARDs, disease‐modifying antirheumatic drugs; PQIs, prevention quality indicators.

a

p < .001.